Inge M. van Oort
YOU?
Author Swipe
View article: Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study Open
Molecular tumour testing should preferably be done on metastatic mCRPC tissue. No combination of features could robustly identify druggable genotypes; therefore, reflex molecular characterisation should be routine for every mCRPC patient.
View article: Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway
Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway Open
Patients with metastatic prostate cancer (mPCa) are eligible for germline genetic testing. This study assessed the experiences of mPCa patients undergoing genetic testing after being counselled by non‐genetic healthcare professionals (ngHC…
View article: Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer Open
Objectives To study the impact of the new MRI pathway and conventional transrectal ultrasound‐guided systematic biopsies (TRUSGB) on anxiety and HRQoL in men with suspected PCa. Materials and methods A secondary analysis was performed of a…
View article: The benefits of <scp>PCNL</scp> combined with ureterorenoscopy compared to isolated <scp>PCNL</scp> in urolithiasis ( <scp>PRECISE</scp> ): a multicentre randomised controlled trial protocol
The benefits of <span>PCNL</span> combined with ureterorenoscopy compared to isolated <span>PCNL</span> in urolithiasis ( <span>PRECISE</span> ): a multicentre randomised controlled trial protocol Open
Background Percutaneous nephrolithotomy (PCNL) often fails to achieve complete stone clearance with a single procedure. Residual fragments, irrespective of size, are associated with increased stone‐related morbidity and a higher likelihood…
View article: Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer Open
Objective To assess the prevalence of germline pathogenic variants (gPVs) in genes associated with female breast cancer in Dutch patients with metastatic prostate cancer (mPCa). Patients and methods In this prospective multicentre cohort s…
View article: From launch to legacy: 10 years of The European Association of Urology Guidelines on social media
From launch to legacy: 10 years of The European Association of Urology Guidelines on social media Open
View article: Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy: 5-year follow-up of a nationwide real-world cohort
Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy: 5-year follow-up of a nationwide real-world cohort Open
Background While overall survival following radical prostatectomy (RP) for localised prostate cancer (PCa) is generally good, biochemical recurrence (BCR) and development of metastases remain challenges, often requiring salvage or palliati…
View article: How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View
How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View Open
A group of Dutch medical specialists discussed on how to diagnose metastatic hormone-sensitive prostate cancer and choose the most appropriate treatment for patients with this condition. It was concluded that imaging based on Prostate-spec…
View article: A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer
A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer Open
View article: Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial
Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial Open
Background Evidence on the efficacy of psychological interventions targeting cancer patients diagnosed with an adjustment disorder is scarce. Aims This study aimed to investigate the efficacy and budget impact of a tailored psychological i…
View article: Moving from a registry to a learning health system: A case study of a Dutch prostate cancer registry
Moving from a registry to a learning health system: A case study of a Dutch prostate cancer registry Open
Introduction Learning health systems (LHSs) are systems that seamlessly embed continuous quality improvement based on real‐world data. To establish LHSs, several infrastructures need to be in place. Registries already have part(s) of this …
View article: Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer
Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer Open
View article: [18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine Open
Aim The objective of this study was to compare the detection rates of [ 18 F]PSMA-1007 and [ 18 F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0.2–5.0 µg/L). M…
View article: Het effect van een gereduceerde dosis enzalutamide op bijwerkingen bij kwetsbare patiënten met prostaatkanker
Het effect van een gereduceerde dosis enzalutamide op bijwerkingen bij kwetsbare patiënten met prostaatkanker Open
Samenvatting Enzalutamide is een sterke remmer van de androgeenreceptor. Behandeling met enzalutamide is effectief bij verschillende stadia van prostaatkanker. De behandeling kan echter gepaard gaan met bijwerkingen, zoals vermoeidheid, co…
View article: P072 The impact of length and location of positive surgical margins on biochemical recurrence after radical prostatectomy: 5-year follow-up of a nationwide crosssectional real-world cohort
P072 The impact of length and location of positive surgical margins on biochemical recurrence after radical prostatectomy: 5-year follow-up of a nationwide crosssectional real-world cohort Open
View article: Supplementary Figure S1 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S1 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Per patient ctDNA fractions and PSA levels at baseline and after 4 weeks of treatment
View article: Supplementary Table S2 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Table S2 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Evidence for ctDNA estimates per patient per timepoint
View article: Supplementary Figure S2 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S2 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
On-treatment ctDNA fraction, PSA and LDH changes and durability of treatment response
View article: Supplementary Methods from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Methods from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Additional methodological details
View article: Supplementary Table S2 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Table S2 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Evidence for ctDNA estimates per patient per timepoint
View article: Supplementary Figure S9 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S9 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Changes in PSA levels between baseline and 4 weeks on-treatment in the different ctDNA kinetics groups
View article: Supplementary Figure S1 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S1 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Per patient ctDNA fractions and PSA levels at baseline and after 4 weeks of treatment
View article: Supplementary Figure S2 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S2 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
On-treatment ctDNA fraction, PSA and LDH changes and durability of treatment response
View article: Supplementary Figure S6 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S6 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Relationship between on-treatment detection of circulating tumor DNA patient outcomes
View article: Supplementary Methods from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Methods from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Additional methodological details
View article: Supplementary Figure S5 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S5 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Relationship between baseline circulating tumor DNA fraction and patient outcomes
View article: Supplementary Table S3 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Table S3 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Multivariable Cox proportional hazards models for time to progression and time to death
View article: Supplementary Figure S4 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S4 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Frequency of recurrent somatic alterations compared to published cohorts
View article: Supplementary Figure S9 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S9 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
Changes in PSA levels between baseline and 4 weeks on-treatment in the different ctDNA kinetics groups
View article: Supplementary Figure S7 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Supplementary Figure S7 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer Open
On-treatment ctDNA fraction, PSA responses and baseline genomic and clinical features